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The Canadian Association of Neuropathologist – Association canadienne des neuropathologistes (CANP-ACNP) 
held their 61st annual meeting via Zoom from October 14th to 16th, 2021, under the leadership of Dr. Peter 
Gould, President of the CANP-ACNP, Dr. Peter Schutz, Secretary Treasurer of the CANP-ACNP, and with tech-
nical support from CANP administrators Heather Dow and Colleen Fifield.  
The academic program comprised 17 scientific abstracts, 8 unknown cases, the Presidential symposium on Epi-
lepsy and Neoplasms, and a Neuropathology in Practice session on the implementation of the new WHO classi-
fication of CNS neoplasms in Canada. Digital pathology images from the 8 unknown cases are available for 
viewing online (www.canp.ca). The unknown case sessions were moderated by Dr. Andrew Gao. 
The Presidential Symposium 2021 on Epilepsy and Neoplasms featured the David Robertson Lecture given by 
Dr. Eleonora Aronica entitled Evolving classification of epilepsy-associated tumors: Understanding epileptogen-
esis, the Gordon Mathieson Lecture delivered by Dr. Harvey Sarnat on Why are some cerebral malformations 
more epileptogenic than others? Clues from developmental neuropathology, and the Jerzy Olszewsky Lecture 
presented by Dr. Maria Thom on Neuropathology in sudden and unexpected death in epilepsy and future direc-
tions. The program was completed Dr. George Ibrahim’s lecture on Epilepsy as a network disorder.  
The Mary Tom Award for best clinical science presentation by a trainee went to Dr. Suzy Kosteniuk (Supervisor 
Dr. S. Das), and the Morrison H. Finlayson Award for best basic science presentation by a trainee was won by 
Dr. Nicole Schwab (Supervisor Dr. L.N. Hazrati). 
The following abstracts were presented at the 61st annual meeting of the Canadian Association of Neuropa-
thologists – Association candienne des neuropathologistes (CANP-ACNP) in October 2021. 
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Histologic and clinical spectrum of brain tumours harbouring 
FGFR3-TACC3 fusions 
Francesca Gianno1, Jennifer A. Chan2, Phedias Diamandis3,4, John A. Maguire5, Qi Zhang6, Cynthia 
Hawkins1, Lili-Naz Hazrati1 
1 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Depart-
ment of Pathology, The Hospital for Sick Children, Toronto, Ontario, Canada 
2 University of Calgary, Calgary, Alberta, Canada 
3 Princess Margaret Cancer Centre/Laboratory Medicine Program, University Health Network, Toronto, Ontario, 
Canada 
4 Departments of Laboratory Medicine and Pathobiology and Medical Biophysics, University of Toronto, Toronto, 
Ontario, Canada 
5 Department of Pathology & Laboratory Medicine, Costal Health-Vancouver General Hospital, Canada 
6 Department of Pathology, London Health Sciences Centre, London, Canada 
Fibroblast growth factor receptor (FGFR) gene family alterations, including point mutations and fusions, have 
been described in brain tumours as oncogenic drivers (NG 2013; 45(6): 602–612). FGFR3-TACC3 fusions were 
initially described in IDH wildtype glioblastomas (Science 2012; 337:1231–1235) and are most frequently seen in 
morphologic or molecular GBM although occasional WHO grade 2 astrocytomas may harbour this alteration. The 
significance of this alteration as a single driver in low-grade glioma is unclear. In order to better understand the 
clinical implications of finding this alteration, a series of low-grade gliomas underwent molecular testing at Sick-
Kids. The series includes six samples of diffuse low-grade gliomas, with a mean age of 24.8 years (range 1 to 44 
years), three males and three females. Five out of six tumours are localized in the supratentorial region, and one 
in the spinal cord. Three patients presented with seizures, one was asymptomatic. Morphologic appearance 
showed different aspects, from cells with oligo-like features in a neuropil-rich stroma to spindle cells with fibril-
lary cytoplasm in a loose microcystic background. Single nucleotide polymorphism (SNP) array was performed 
on two samples and one of them shows the gain of chromosome 7 and loss of chromosome 10, indicating a 
molecular profile of high grade glioma. Follow-up was available for four patients, all are alive without progressive 
disease with follow-up ranging from six months to two years. Longer follow-up will be required to determine the 
significance of this alteration in low grade glioma. 
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Ganglion cell maturational markers in peripheral neuroblastic 
tumours of children 
Harvey B. Sarnat1 
1 University of Calgary & Alberta Children's Hospital, Calgary, Alberta, Canada 
Peripheral neuroblastic tumours of neural crest origin are the most frequent solid neoplasms outside the CNS in 
children. Neuroblastoma/ganglioneuroblastoma have a natural evolution of histological differentiation over 
time. Together with mitosis-karyorrhexis index and patient age (International Neuroblastoma Pathology Classifi-
cation criteria), ganglion cell maturation determines grading and prognosis. Maturation presently is assessed 
only by H&E histology. 
 
Methods: Immunocytochemical markers of neuroblast maturation in fetal CNS were applied to peripheral neu-
roblastic tumours arising in adrenal medulla or sympathetic chain. Resected tumours of 4 toddlers were exam-
ined using antibodies demonstrating neuronal identity and maturation: MAP2; synaptophysin; chromogranin-A; 
NeuN; keratan sulfate (KS); glutamate receptor antibody (GluR2). Others: Ki67; S-100β protein; vimentin; nestin; 
α-B-crystallin; neuroblastoma marker PHOX2B. 
 
Results: Degrees of neuroblastic maturation were demonstrated by MAP2, chromogranin, synaptophysin, KS and 
GluR2; NeuN was negative consistent with sympathetic neural crest lineage. KS was sparsely distributed within 
the tumours adherent to somata and proximal neuritic trunks. PHOX2B did not distinguish maturational stages. 
Ki67 was expressed in scattered primitive cells that also expressed vimentin and nestin, but not in differentiated 
neoplastic neurons. S-100β protein and α-B-crystallin labeled Schwann cells, especially Schwannian ganglioneu-
roma. 
 
Conclusions: Immunocytochemical markers of neuroblast maturation in fetal brain also are useful in peripheral 
neuroblastic tumours, providing greater precision than histology alone. The most practical are MAP2 and synap-
tophysin. Prognosis and choice of treatment including chemotherapy might be influenced. 
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Long term disease-free survival after surgical resection only: 
Malignant IDH-mutated astrocytoma versus ganglioglioma 
Roland N. Auer1,5, Egiroh Omene2, Sarah E. Edwards1, Kotoo Meguro1, Daryl R. Fourney1, Jose F. Tellez-
Zenteno2, Gary R. W. Hunter2, Kyle Moulton3, Vijayananda Kundapur4 
1 Department of Surgery (Neurosurgery) , University of Saskatchewan, Saskatoon, Saskatchewan, Canada 
2 Department of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada 
3 Department of Radiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada 
4 Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada 
5 Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, 
Canada 
Gangliogliomas are important to distinguish from anaplastic astrocytoma and glioblastoma multiforme, to avoid 
potentially damaging radiation and for accurate prognostication. Two patients with a seizure presentation at age 
31 and 30 had large, well demarcated brain tumors each 4.3 cm with no suggestion of diffuse glioma on imaging. 
Both patients requested tumor resection. The first patient intra-operatively was found to have the tumor in close 
proximity to the motor cortex, and resection was thus incomplete, leaving residual tumor in situ. The second 
patient had a gross total resection. An initial diagnosis of ganglioglioma, was changed to malignant astrocytoma 
based on IDH1 mutation, loss of ATRX, abundant mitoses and a high Ki67 labelling index. Conventional histology 
revealed glial, neuronal and intermediate forms in both tumors. Both patients declined treatment following neu-
rosurgery and remain without tumor growth on neuroimaging at 6 and 3 years later, respectively. The findings 
illustrate the conundrum of tumors diagnosed as malignant astrocytomas based on molecular profile, but show-
ing no growth after no treatment, as well as the superiority of resection over needle biopsy, as the first tumor 
was called a diffuse astrocytoma on a needle biopsy prior to resection. Without diffuse astrocytoma appearing 
on long-term follow-up in the absence of radiochemotherapy, a diagnosis of diffuse, malignant astrocytoma is 
increasingly untenable as years pass. Both patients and their clinicians question the malignant diagnosis. Gangli-
ogliomas have been reported with IDH mutation (Brain Pathol 2011; 21: 564-574). Ganglioglioma versus diffuse 
astrocytoma remains a difficult differential diagnosis in neuropathology.  
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Diagnostic challenges in unusual high-grade gliomas 
Namita Sinha1, Arie Perry2 
1 Department of Pathology, Health Sciences Center, University of Manitoba, Winnipeg, Manitoba, Canada 
2 Department of Pathology, University of California, San Francisco, California, USA 
Diagnosis of most of adult high-grade gliomas is largely based on morphology and immunohistochemistry, with 
an increasing role of molecular studies to aid proper classification (IDH wildtype and IDH-mutant gliomas, 
H3K27M mutant diffuse midline glioma). On occasions, despite all the work-up, the results do not allow for a 
definite diagnosis that are established in the most recent WHO classification. Some glial tumor shows dediffer-
entiation and looses GFAP expression. In these cases, methylation profiling is a power tool in establishing the 
diagnosis. Therefore, it is very important that the tissue should be utilized optimally and carefully especially when 
the biopsies are very small and extensive work may be required. On rare occasions, definitive diagnosis can be 
challenging despite complete histological and molecular characterization. Some variants of glioblastoma may 
show epithelial or primitive neuronal differentiation and some variants may have increased predilection for CSF 
metastasis and therefore it is important to subclassify these variants. These challenges will be discussed with 
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Regional variability of α-synuclein inclusion size in multiple 
system atrophy 
Ain Kim1,2,3, Ivan Martinez-Valbuena2,3, Gabor G. Kovacs1,2,3* 
1 Department of Laboratory Medicine & Pathobiology, University of Toronto, Ontario, Canada 
2 Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Ontario, Canada 
3 Krembil Research Institute, University Health Network, Ontario, Canada 
Relevance: Multiple system atrophy (MSA) patients show variable duration of illness and distinct constellation 
of clinical symptoms suggestive of different pathological α-synuclein strains.  
 
Objective: Based on this, our aim is to investigate whether the seeding and aggregation process of α-synuclein 
are different in MSA brains, leading to variability of size and detectability of oligodendrocytic inclusions using 
different anti-α-synuclein antibodies. 
 
Methods: The putamen and cerebellum of 6 MSA cases were immunostained using nitrated, truncated, phos-
phorylated and disease-specific α-synuclein (clone 5G4) antibodies. Sections were scanned using TissuescopeTM 
and images were processed using Photoshop (v.21.0.3). 5G4-immunoreactive oligodendrocytes with visible nu-
cleus were optically dissected and inclusion sizes were evaluated using algorithms that we developed using the 
software Image J.  
 
Results: The size of 5G4-reactive inclusions were significantly larger in the cerebellum than in the putamen in 4 
out of 6 cases. In one case, the inclusion size was significantly larger in the putamen than in the cerebellum, while 
a single case showed similar sizes. In addition, case-wise comparison revealed significant variability between the 
size of inclusions in both regions. In addition, substantial differences were noted between the number of inclu-
sions stained by the different α-synuclein antibodies. 
 
Conclusions: We developed a novel computer-based method to measure the size and number of α-synuclein 
inclusions in MSA. Our observations on the variability of size and number of inclusions, detected by different α-
synuclein epitopes between brain regions and cases, support the notion of distinct subtypes of disease. Our study 
further provides a first step to developing AI-based evaluation strategies for large scale comparative studies. 
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Cognitive resilience in individuals with severe Alzheimer’s 
disease neuropathology 
Narges Ahangari1, Corinne E. Fischer2,3,4, Tom A. Schweizer2,4,5, David G. Munoz1,2,6 
1 Division of Pathology, St. Michael’s Hospital, Toronto, Ontario, Canada 
2 Keenan Research Centre for Biomedical Research, The Li Ka Shing Knowledge Institute, St.Michael’s Hospital, 
Toronto, Ontario, Canada 
3 Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario, Canada 
4 Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada  
5 Division of Neurosurgery, Faculty of Medicine, University of Toronto, Ontario, Canada 
6 Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada  
We sought to identify demographic, clinical, genetic, and neuropathological features associated with cognitive 
resilience in subjects with severe Alzheimer’s disease (AD) neuropathology. Data for this study was obtained 
from a National Alzheimer’s Coordinating Centre (NACC) dataset. Study inclusion criteria are as follows: severe 
AD pathology, i.e., frequent neuritic plaques and Braak & Braak stage V/VI pathology, interval between last visit 
and death ≤ 2 years, and absence of other primary neuropathology diagnoses. Cognition was assessed by the 
Mini-Mental Status Examination (MMSE) score. A total of 654 cases met our criteria. Of these, 59 (9%) persons 
had MMSE scores ≥24 at their last visit and were categorized as cognitively resilient. First, bivariate analysis was 
done to compare resilient with non-resilient groups. Then, variables with significant results were entered into 
the multivariable model. Based on our binary logistic regression model, resilient subjects were older (odds ratio 
[OR]=1.03; 95% confidence interval [CI]=1–1.07), had more years of education (OR=1.16; 95% CI=1.04-1.29), had 
lower BMI (OR=0.91; 95% CI=0.85-0.99), were more likely to be a smoker (OR=2.78; 95% CI=1.45-5.34), and were 
more likely to use an anticoagulant/antiplatelet at last visit compared with subjects with impaired cognition 
(OR=1.87; 95% CI=1.01-3.48). In addition to expected protective factors such as higher education and lower BMI, 
our results showed that more smoking and frequent use of an anticoagulant/antiplatelet at last visit could also 
be possibly associated with resilience to clinical expression of AD severe pathology. Pharmacological approaches 
that mimic the effects of nicotine may be useful in amelioration of AD symptoms. 
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Linking iron homeostasis to vulnerability patterns in progressive 
supranuclear palsy 
Seojin Lee1, Ivan Martinez-Valbuena1, Suganthini Ilaalagan1,3, Naomi P. Visanji2,4, Gabor G. Kovacs1,2,3,4 
1 Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada 
2 Department of Laboratory Medicine and Pathobiology and Department of Medicine, University of Toronto, 
Toronto, Ontario, Canada 
3 Laboratory Medicine Program & Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada 
4 Edmund J. Safra Program in Parkinson’s Disease and Rossy Program in Progressive Supranuclear Palsy, Toronto 
Western Hospital, Toronto, Ontario, Canada 
Progressive Supranuclear Palsy (PSP) is a 4-repeat tauopathy in which pathology starts in select subcortical areas 
including the globus pallidus (GP) and the substantia nigra (SN), regions also associated with age-related iron 
accumulation. Toxic iron burden in these regions of PSP brains have been examined but given the differences in 
cellular iron homeostasis across cell types and the heterogeneity in PSP tau cytopathology, we aim to examine 
the possible role of iron accumulation on the cellular selective vulnerability of tau pathology in the vulnerable 
anatomical regions of PSP brains. Using human post-mortem brain tissue of the early-affected PSP brain regions 
(GP, SN, and putamen), we visualized iron deposition in the neurons, astroglia, oligodendrocytes, and microglia 
using a combination of DAB-enhanced Perl’s (ferric) and Turnbull (ferrous) iron staining with immunohistochem-
istry of cell type-specific markers. Iron deposition was also examined in relation to their tau cytopathologies using 
AT8-immunohistochemistry. In all three regions, astrocytes and microglia were seen to predominantly accumu-
late both species of iron. Moreover, tau-positive astrocytes showed the highest frequency of cellular iron depo-
sition compared to neurofibrillary tangles and oligodendroglial coiled bodies. On the other hand, association of 
iron burden with different cellular tau pathologies was species-specific in the same regions, suggesting iron func-
tions in PSP tau cytopathology may be distinct by species. Our mapping of cellular iron burden in relation to 
pathology in PSP brains suggests a selective cellular vulnerability to iron deposition in diseased brains, and further 
supports the role of pathological iron in the early pathogenesis of PSP.  
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Friedreich cardiomyopathy is a secondary desminopathy 
Arnulf H. Koeppen1,6, Rahman F. Rafique1, Joseph E. Mazurkiewicz2, Steven Pelech3,4, Catherine Sutter3, 
Qishan Lin5 , Jiang Qian6 
1 Research Service, Veterans Affairs Medical Center, Albany, New York, USA 
2 Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York, USA 
3 Kinexus Bioinformatics Corporation, Vancouver, British Columbia, Canada 
4 Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Ca-
nada 
5 RNA Epitranscriptomics & Proteomics Resource, University at Albany, Albany, New York, USA 
6 Department of Pathology, Albany Medical College, Albany, New York, USA 
Hypertrophic cardiomyopathy with or without arrhythmia is the predominant cause of death in Friedreich ataxia 
(FA). The clinical and pathological phenotypes of FA are diverse. The pathogenesis of the FA-related lesions in 
the central and peripheral nervous systems, heart, skeleton, and endocrine pancreas is incompletely understood. 
The hypothesis in this research is that frataxin deficiency affects the cellular proteome in downstream mecha-
nisms. Antibody microarrays of pooled FA heart lysates showed upregulation in several proteins, including alpha 
B crystallin, a desmin chaperone. Western blots of individual and pooled heart lysates revealed a prominent extra 
desmin band at 47 kDa that was absent or under-expressed in control samples. Mass spectrometry confirmed 
the origin of this band from canonical desmin (53 kDa). Co-immunoprecipitation of FA heart lysates with anti-
desmin, recovery of the antigen-antibody complex with protein A-Sepharose, sodium dodecylsulfate polyacryla-
mide gel electrophoresis, and Western blotting confirmed the interaction of desmin and αB crystallin. Slide tech-
niques, including immunohistochemistry and double-label immunofluorescence, disclosed desmin and alpha B 
crystallin aggregation near intercalated discs and Z-discs. Congo Red fluorescence microscopy did not confirm 
the formation of amyloid. We suggest that accumulation of a truncated desmin and aggregation with αB crystallin 
cause accelerated heart disease in FA. 
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Glial senescence (not tau) is the driver of post-concussive 
symptoms 
Lili-Naz Hazrati1,2, Nicole Schwab1,2 
1 The Hospital for Sick Children, Toronto, Ontario, Canada 
2 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada 
Mild traumatic brain injury (mTBI) leads to chronic symptoms in some patients. Pathologically, mTBI is associated 
with chronic traumatic encephalopathy (CTE), a neurodegenerative disease characterized by hyperphosphory-
lated tau (p-tau) in neurons and astrocytes at the depths of cortical sulci. CTE has been proposed as the driver of 
these symptoms, despite many patients presenting with severe symptoms yet minimal pathology. It is known 
that low levels of p-tau are present in cognitively intact individuals, including ageing-related tau astrogliopathy 
(ARTAG), and that p-tau accumulates prior to a diagnosis of Alzheimer’s disease. We propose that examining 
changes beyond p-tau is critical to understand mTBI pathology. 
 
The objective of this study is to identify novel pathological markers of mTBI which may explain clinical symptoms 
and allow for the development of therapeutic targets. 
 
Using a brain bank of former professional athletes with mTBI history we used immunohistochemistry and gene 
expression analysis to show cellular senescence as a mechanism driving brain dysfunction after mTBI. Compared 
to controls, mTBI brains show widespread DNA damage (γH2AX) and cellular senescence in ependymal cells, 
astrocytes, and oligodendrocytes even in cases with no neuropathology. Gene expression analysis revealed up-
regulation of the senescence-associated secretory phenotype (SASP), a form of chronic low-level inflammation 
which has been proposed to drive cognitive dysfunction and proteinopathy. In a mouse model of mTBI, we have 
recapitulated these results and shown that eliminating senescent cells with senolytic therapy is beneficial. 
 
mTBI brains are characterized by early ageing through cellular senescence, which may drive clinical symptoms 
and p-tau pathology. 
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Hail to astrogliosis! The unsung hero of the CNS tissue reaction 
to the spinal cord injury 
Jacek M. Kwiecien1 
1 Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, 
Ontario, Canada 
Spinal trauma results in a localized spinal cord injury (SCI) with an area of hemorrhage and necrosis surrounded 
by edema in Acute Phase that lasts 2 days followed by an Inflammatory Phase beginning on day 3 with infiltration 
of necrosis by inflammatory CD68+/CD163- macrophages whose numbers rapidly increase and persist at high 
levels for 4 weeks and then decline but are still present in low numbers at 16 weeks. This destructive inflamma-
tion is fuelled by myelin-rich necrotic debris and the macrophage activation causes ongoing damage to the sur-
rounding spinal cord and further damaged myelin to sustain a mechanism of vicious cycle. The severity of post-
SCI inflammation becomes inhibited and eliminated by a spinal cord tissue response in the 3rd Phase, Resolution. 
Astrogliosis is a hallmark of reaction to SCI. In the 1st week astrocytes surrounding the lesion hypertrophy and 
define a cavity of injury (COI) containing macrophage-rich inflammation and accumulation of water. Progression 
of severity of astrogliosis around the COI coincides with the reduction of numbers of macrophages and leads to 
formation of quiescent syrinx. While the inflammation in the COI leads to damage of blood vessel in the sur-
rounding spinal cord resulting in vasogenic edema beyond 16 weeks post-SCI, astrocytes equipped with aqua-
porin-4 pass excess edema water to 4 extra-spinal spaces; (1) the sub-arachnoid, (2) the central canal, (3) the 
blood vessels, and (4) the COI, a novel mechanism. Astrogliosis is a beneficial element in neuroplasticity following 
the SCI and should not be inhibited in anti-inflammatory treatments effecting neuroprotection. 
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Ischemic-like pathology in aberrant white matter tracts of fetal 
holoprosencephaly: A case series 
Sumit Das1, Jessica Saunders2, Sarah Nikkel3, Lindsay Brown4, Christopher Dunham2 
1 Department of Pathology and Lab Medicine, University Hospital, Edmonton, Alberta, Canada 
2 Division of Anatomical Pathology, BC Children’s Hospital, Vancouver, British Columbia, Canada 
3 Department of Medical Genetics, BC Children’s Hospital, Vancouver, British Columbia, Canada 
4 Division of Genome Diagnostics, BC Children’s Hospital, Vancouver, British Columbia, Canada 
Holoprosencephaly (HPE) is due to defective early forebrain induction resulting in a “lack of cleavage” of the 
primitive prosencephalon into paired cerebral hemispheres. HPE is generally considered sporadic, although clear 
environmental and genetic factors have been recognized. From a genetic perspective, an autosomal dominant 
inheritance pattern is most commonly noted. Chromosomal abnormalities are common in HPE, seen in 25-50% 
of affected individuals, with Trisomy 13 being the most frequent. A number of structural chromosomal abnor-
malities (e.g., 21q22.3 deletion) and pathogenic copy number variations have also been described, as have syn-
dromic associations. Pertinent biologic pathways include SHH, NODAL and BMP; in turn, several single gene mu-
tations related to these pathways have been uncovered, including SHH, ZIC2, and SIX3. Although not frequently 
emphasized in neuropathologic descriptions of HPE, abnormal white matter has been reported, mainly in the 
form of aberrant tracts (e.g., absence of the corpus callosum and hypoplasia of the corticospinal pathway). In 
this study, we detail the clinicopathologic features of 8 fetal BCCH cases bearing a seemingly unique dual form 
of white pathology. All 8 cases demonstrated ischemic-like pathology, with 7 of 8 exhibiting such pathology in a 
similar location – ventral to the fused deep grey nuclei. Diffusion tensor imaging (DTI) studies suggest that the 
neuroanatomic substrate of this aberrant white matter is fused superior and inferior occipito-frontal fasciculi, 
with the resultant fibers crossing the midline. While the etiology of this ischemic-like pathology is unclear, the 
literature raises the possibility of a role for the SHH pathway.  
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Brain pathology in patients with congenital heart disease 
Murad A. Alturkustani1,2,3, Linda J. Szymanski2 
1 King Abdulaziz University, Jeddah, Saudi Arabia 
2 Children’s Hospital Los Angeles, Los Angeles, California, USA 
3 Western University, London, Ontario, Canada 
Brain pathology in patients with congenital heart disease (CHD) are associated with neurodevelopmental delay. 
Imaging studies support vascular etiology for both white and gray matter lesions. In this retrospective study, we 
describe the pathological changes in the brains of patients with CHD. The last 20 autopsy cases in patients with 
CHD at our institution were retrieved and the clinical and the autopsy report were reviewed. The available H&E, 
special, and immunostains were evaluated and at least one section from each case was stained with GFAP, APP, 
and HLA-DR. Five control cases included telencephalic leukoencephalopathy (3) and no significant pathological 
changes (2). The following histological features were assessed: necrotic cells in cortex, hippocampus and the 
cerebellum; APP and GFAP staining pattern, and presence of focal lesions and amphophilic globules. Twenty 
patients (10 males, 10 females) were identified with age range of 2 weeks – 19 years. The pathological findings 
are as follows: 8 cases had changes consistent with acute global hypoperfusion, 5 cases showed features con-
sistent with chronic global hypoperfusion, 3 cases showed focal white matter lesions (1 secondary, to septic 
emboli), 4 cases with only widespread gliosis, one case with only old focal neuronal loss in dentate gyrus, and 
one with no significant changes. Subarachnoid hemorrhages were present in 5 cases and germinal matrix hem-
orrhage in 3 cases. In conclusion, most of the pathological changes could be explained by cerebral hypoperfusion 
and better techniques to improve the cerebral perfusion are warranted in the management of these patients.  
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Characterizing the hippocampal dentate gyrus involvement in 
temporal lobe epilepsy 
Carolyn Twible1, Qi Zhang1,2 
1 Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western Univer-
sity, London, Ontario, Canada 
2 Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada 
Hippocampal sclerosis (HS) is the most common pathology finding for drug resistant temporal lobe epilepsy (TLE) 
and is characterized by neuronal loss and gliotic Cornu Ammonis. Nearly 20% of surgical specimens from drug-
resistant TLE surgery contain “normal” populations of neurons, termed no-HS, yet still benefit from surgical re-
section. This observation suggests a neuropathological explanation for the epileptogenic focus in the resected 
tissue that is not detected through standard diagnostic practices. The goals of this project are to increase the 
neuropathological understanding of drug resistant TLE, and to elucidate the structural changes of HS and no-HS, 
focusing on the granule cell layer (GCL). In this study, 21 TLE surgical resection cases were examined, including 
14 HS and 7 no-HS cases, to investigate GCL morphometry. Information on histopathological diagnosis and post-
operative outcome were collected. The digital image analysis software QuPath was used to perform cell detec-
tion analysis on the GCL. Measures including Delaunay mean cell density were analyzed. HS patients show a 
significant increase in granule cell spacing and decrease in granule cell density within the GCL compared to no-
HS patients. Regardless of the histological diagnosis, patients who achieved seizure freedom post-operatively 
demonstrated an increase in granule cell spacing and decrease in granule cell density in comparison to those 
who did not achieve seizure freedom post-operatively. HS and no-HS diagnosis groups have disease- and post-
operative outcome dependent morphometry differences. The post-operative outcome dependent morphometry 
observed in HS and no-HS patients presents a potential additional method to evaluate post-operative prognosis 
for TLE surgical-resection patients. 
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Deep learning approaches to deciphering intra-tumoural 
heterogeneity in glioblastoma 
Anglin Dent1, Brian Lam1, Kevin Faust1, Alberto J. Leon3, Phedias Diamandis1 
1 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada 
Background: Emerging evidence strongly implicates intra-tumoral heterogeneous biology in treatment re-
sistance and disease progression across many cancer types (1). Using glioblastoma (GBM) as a prototype, I have 
aimed to leverage the computational power of Artificial Intelligence (AI) and deep learning (2) to develop an 
autonomous workflow for the objective definition and quantification of biologically distinct tumour subpopula-
tions. 
 
Objectives: I hypothesize that AI-defined tumoral clusters predict spatially distinct molecular profiles and thera-
peutic targets. 
 
Methods: I apply our developed image clustering workflows (3) to quantify AI-defined subregions within a clinical 
cohort of 10 GBM patient tumors and use laser capture microdissection and mass spectrometry-based prote-
omics to address if AI-defined subregions show intra-tumoral molecular variation. Further, I leverage existing 
pharmacogenomic databases (4) and carry out drug sensitivity and transcriptional clustering to define bi-
omarkers and validate their intra-tumoral expression in my clinical GBM cohort. 
 
Results: Preliminary data shows that region-to-region heterogeneity can be found in IDH wild-type GBM using 
our unbiased omics approach, in addition to predicting different pharmacogenomic sensitivities. 
 
Conclusions: This project aims to develop the first AI-driven tool to guide the routine and systematic molecular 
analysis of spatial morphogenomic heterogeneity. Further, this tool may have the potential to provide novel 
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Integrating morphologic and molecular histopathological features 
through whole slide image registration and deep learning 
Michael K. Lee1, Kevin Faust2,3, Anglin Dent1, Clare Fiala3, Alessia Portante1, Madhu Rabindranath1, Noor 
Alsafwani3,4, Andrew Gao1,3, Ugljesa Djuric5, Phedias Diamandis1,3,5,6 
1 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada 
2 Department of Computer Science, University of Toronto, Toronto, Ontario, Canada 
3 Laboratory Medicine Program, Department of Pathology, University Health Network, Toronto, Ontario, Canada 
4 Department of Pathology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia 
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada 
6 Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada 
Background and Objective: Despite recent innovations in deep learning, integrating histomorphologic and mo-
lecular information found on respective H&E and IHC-stained tissue sections still remains a challenge. While hu-
man observers can easily align these different tissue sections, routine computational approaches for image reg-
istration of giga-byte sized WSIs are still needed. Here, we aim to address this issue by incorporating another 
computer vision tool, scale-invariant feature transform (SIFT), to align H&E-stained sections with accompanying 
IHC studies for automated subclassification of gliomas. 
 
Method: To test the workflow, we first trained a VGG19 convolutional neural network (CNN) using pathologist-
annotated H&E WSIs to recognize histological patterns of 16 common tissue and lesion classes. Afterwards, we 
optimized a different set of CNNs to recognize various IHC markers, such as IDH1-R132H and ATRX, which are 
relevant for molecular subclassification of gliomas. For the integrated analysis, we employed SIFT to find features 
for image matching which were used to align lesional regions of H&E and IHC slides. 
 
Results: The histomorphologic classifier (CNNH&E) excelled at classification with accuracies of 100% for glioma, 
meningioma and metastatic carcinoma, and 93% for schwannoma (n = 125). Using the newly developed CNNH&E 
and SIFT-based alignment, the quantitative analysis by the IHC classifiers significantly improved for ATRX retained 
and IDH1-R132H positive WSIs when compared to that of unaligned WSIs. 
 
Conclusion: SIFT can work in concert with deep learning tools to provide a pathologist-inspired workflow to help 
automate advanced immunohistochemically diagnostic tasks, such as subclassification of glioma. 
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Neuropathology of eight cases of the New Brunswick cluster of 
Neurological Syndrome of Unknown Cause (NSUC) 
Gerard H. Jansen1, Sidney E. Croul2, Angela K. Miller3, Alexander S. Easton2, John M. J. Woulfe1 
1 Department of Pathology and Laboratory medicine, University of Ottawa, Ottawa, Ontario, Canada 
2 Department of Pathology, QEII Health Science Centre, Halifax, Nova Scotia, Canada 
3 Department of Pathology, Health Sciences Centre, Winnipeg, Manitoba, Canada (previously Department of Pa-
thology, Moncton Hospital, Moncton, New Brunswick, Canada) 
On March 17, 2021 a press conference aired featuring a Moncton neurologist and New Brunswick’s Chief Medical 
Health Officer, regarding a cluster of patients in New Brunswick who had symptoms reminiscent of CJD, and were 
claimed to have a novel neurological syndrome. The onset of the disease was between 2015 and 2021. All pa-
tients in that cluster had at that time been reported by one neurologist, although subsequently a few incidental 
cases were reported by other neurologists. The size of this cluster has been reported at around 50 cases. Further 
news publications have suggested that an environmental factor is the causative factor for this cluster. 
 
This news has significantly disturbed the medical community. Since 2019 eight patients have died that belonged 
to this cluster. We report their neuropathological findings and hope this will bring some clarity.  
 
There was one case of metastatic carcinoma, one case of FTLD-TDP43, one case of neocortical Lewy body pathol-
ogy, one case of neocortical Lewy body pathology and AD, 2 cases of AD with vascular pathology, one case of 
mainly vascular pathology, and one case without significant pathology (consistent with the patient’s previous 
history). In these 8 patients no evidence for a prion disease was found, nor novel pathology. We suggest that 
these 8 patients represent a group of misclassified clinical diagnoses.  
 
Since June 3, 2021 the Oversight Committee was established in New Brunswick reviewing the clinical and epide-
miological data of the patients in this cluster. We hope that our findings are useful to them. 
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COVID-19 pandemic impact on surgical neuropathology services 
at London Health Sciences Centre 
Shervin Pejhan1, Chris Tran1, David Driman1, Robert Hammond1,2, Lee Cyn Ang1,2, Qi Zhang1,2 
1 Department of Pathology & Lab Medicine, London Health Sciences Centre, London, Ontario, Canada 
2 Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada 
The COVID-19 pandemic has had a significant impact on medical services. Many jurisdictions postponed non-
urgent procedures to balance individual patient care with public health precautions. Surgical backlogs caused by 
the COVID-19 pandemic have been evaluated by different groups. However, the impact of this pandemic on 
pathology and specifically neuropathology (NP) services has received limited attention. In this study, we reviewed 
all surgical NP reports of our centre from March 2018 (two years before the pandemic declaration) through July 
2021. Patient demographic information and pathological variables were collected. For tumours, site, type, and 
WHO grade were analyzed. 
 
Within the period under study, the total number of NP samples was lowest in April 2020, corresponding to the 
first Ontario provincial lockdown. In comparison to the dramatic decrease in other surgical pathology subspecial-
ties (CAMJ 2021;193(10): E343), the NP surgical specimen initially had a minimal volume reduction, with a rapid 
return to baseline. Among the different types of NP surgical specimens, muscle biopsy and epilepsy-related spec-
imens showed a more significant reduction. There was a slight increase in higher-grade tumours. Interestingly, a 
gradual increase of brain biopsies for inflammatory conditions was noticed. 
 
Our results show that the neuropathology service volume reduction due to the COVID-19 pandemic has not been 
as significant as other pathology subspecialties. Studying the variations in histopathological diagnoses in pan-
demic years could be helpful for future planning in both clinical and pathological sectors, especially when the 
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